25 related articles for article (PubMed ID: 30562709)
1. Ligand-Enabled Copper-Mediated Radioiodination of Arenes.
McErlain H; Andrews MJ; Watson AJB; Pimlott SL; Sutherland A
Org Lett; 2024 Feb; 26(7):1528-1532. PubMed ID: 38335124
[TBL] [Abstract][Full Text] [Related]
2. [A simple and rapid routine preparation of no-carrier added meta-I-123- and I-131-iodobenzylguanidine (I-123-MIBG and I-131-MIBG) for clinical nuclear medicine applications].
Samnick S; Kirsch CM
Nuklearmedizin; 1999; 38(7):292-6. PubMed ID: 10599069
[TBL] [Abstract][Full Text] [Related]
3. Development and validation of a LC-MS/MS method for in vivo quantification of meta-iodobenzylguanidine (mIBG).
López Quiñones AJ; Shireman LM; Wang J
J Chromatogr B Analyt Technol Biomed Life Sci; 2021 Sep; 1181():122927. PubMed ID: 34530306
[TBL] [Abstract][Full Text] [Related]
4. Quality control of iodine-131-labeled metaiodobenzylguanidine.
Taşdelen B; Kam E; Asliyuksek H
Nucl Med Commun; 2014 Jan; 35(1):95-8. PubMed ID: 24162836
[TBL] [Abstract][Full Text] [Related]
5. A convenient solution-phase method for the preparation of meta-iodobenzylguanidine in high effective specific activity.
Donovan AC; Valliant JF
Nucl Med Biol; 2008 Oct; 35(7):741-6. PubMed ID: 18848658
[TBL] [Abstract][Full Text] [Related]
6. The vial kit formulation for preparation of no-carrier-added
Chen Z; Wang G; Xie M; Huang H; Wu E; Wang Y
J Labelled Comp Radiopharm; 2018 Feb; 61(2):107-111. PubMed ID: 28833455
[TBL] [Abstract][Full Text] [Related]
7. Use of ESI-MS for semi-quantitative estimation of inactive precursor in no-carrier-added
Mathur A; Das S; Sakhare N; Sachdev SS
J Pharm Biomed Anal; 2019 Feb; 165():261-267. PubMed ID: 30562709
[TBL] [Abstract][Full Text] [Related]
8. Radioiodinated metaiodobenzylguanidine (MIBG): radiochemistry, biology, and pharmacology.
Vallabhajosula S; Nikolopoulou A
Semin Nucl Med; 2011 Sep; 41(5):324-33. PubMed ID: 21803182
[TBL] [Abstract][Full Text] [Related]
9. Forced degradation and impurity profiling: recent trends in analytical perspectives.
Jain D; Basniwal PK
J Pharm Biomed Anal; 2013 Dec; 86():11-35. PubMed ID: 23969330
[TBL] [Abstract][Full Text] [Related]
10. Meta-iodobenzylguanidine and analogues: chemistry and biology.
Vaidyanathan G
Q J Nucl Med Mol Imaging; 2008 Dec; 52(4):351-68. PubMed ID: 19088690
[TBL] [Abstract][Full Text] [Related]
11. The effect of the mobile phase additives on sensitivity in the analysis of peptides and proteins by high-performance liquid chromatography-electrospray mass spectrometry.
García MC
J Chromatogr B Analyt Technol Biomed Life Sci; 2005 Oct; 825(2):111-23. PubMed ID: 16213445
[TBL] [Abstract][Full Text] [Related]
12. Theranostics: evolution of the radiopharmaceutical meta-iodobenzylguanidine in endocrine tumors.
Sisson JC; Yanik GA
Semin Nucl Med; 2012 May; 42(3):171-84. PubMed ID: 22475426
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
